Company / SG&A Expense
ImageneBio, Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.4M
FY2025
5-year range
$8.4M / $24.9M
FY2021-FY2025
Trend
-66.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $22M to $8M over the past 2 years.
Based on SEC 10-K filings.
$8M in FY2025 with a 3-year CAGR of -22.5%.
Improved from $22M to $8M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -22.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -22.5%, indicating a declining trend.
- In FY2025, sg&a expense decreased 66.3% year-over-year.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.4M | -66.3% |
| FY2024 | $24.9M | +12.3% |
| FY2023 | $22.2M | +23.2% |
| FY2022 | $18.0M | +103.2% |
| FY2021 | $8.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026